Skip to main content
Avience Biomedicals IPO
269.23xsubscribed

Avience Biomedicals IPO

Hospital & Healthcare Services
listed
₹2.35LMin. investment

Avience Biomedicals Limited IPO Details

SectorHospital & Healthcare Services
Price range₹196 – ₹208
IPO type
SME
Lot size600 shares
Issue size₹30Cr
Red Herring Prospectus
Read
Market cap
₹114.09CrLower than sector avg
RevenueApr 209 - Mar 2010
₹45.24CrLower than sector avg
Growth rate3Y CAGR
88.81%

Avience Biomedicals IPO Subscription Status

Date
QIB
NII
Retail
Total
18-Jun-26
0.0 times (X)
4.05 times (X)
0.0 times (X)
7.44 times (X)
19-Jun-26
0.01X
20.06X
0.0X
30.61X
22-Jun-26
78.78X
179.69X
0.0X
269.23X

As on 18-Jun-26, 5:30 PM

Avience Biomedicals IPO Timeline

  1. Pre-apply
    17 Jun 2026
  2. Bid start
    18 Jun 2026
  3. Bid end
    22 Jun 2026
  4. Allotment
    23 Jun 2026
  5. Release of funds
    24 Jun 2026
  6. Demat transfer
    24 Jun 2026
  7. Listing
    25 Jun 2026

About Avience Biomedicals Limited

Established in 2019, Avience Biomedicals is a medical consumables and diagnostics company involved in manufacturing of in-vitro diagnostic (IVD) products, rapid test kits, reagents, analyzers, culture media and other medical devices, as well as trading and distribution of diagnostic equipment.
The company has been established under the brand name, "Avienbio". It manufactures its products from an owned manufacturing facility located in Uttar Pradesh. The company also plans to expand its manufacturing and has received an allotment of 2,100 sq. mtr. commercial plot in Medical Device Park, YEIDA along with 1,000 sq. mtr. industrial plot in Yamuna expressway.
The company has scaled up its product basket from primarily COVID-related diagnostics kits to include dengue, malaria, HIV, HBsAg, HCV, syphilis, typhoid and pregnancy rapid test kits, molecular diagnostics, culture media, biochemistry reagents, electrolyte analyzer, oxygen concentrator and lab consumables along with being a trader of diagnostics instruments and an authorized channel partner to some of the leading diagnostics equipment brands.
The business has a diversified customer base including B2B distributors/traders, B2C hospitals and diagnostic laboratories and B2G government entities. The sales revenue comprises various sources, and B2B and B2C sales each hold over 45% of the sales revenue.
The sales revenue for the period ended on January 31, 2026 is made up of 45.3% B2B sales, 45.2% B2C sales, 7.8% government sales, and 1.8% export sales. Capacity utilisation for the rapid test kits is 84.1%. The manufacturing capacity for rapid test kits has grown significantly since FY23 and the utilization of this manufacturing capacity as of January 2026 is 84.1% compared to five lakh tests utilized during FY23. Analyzer manufacturing utilization was 80.6%, while reagent and consumable manufacturing utilization was 85.2% for the period ending January 31, 2026.
Majority of the sales revenue originates from North India with the two major states of Delhi and Uttar Pradesh combined contributing over 76% of total sales revenue as of January 31, 2026. The sales revenue was attributed to Delhi by 42.2% and Uttar Pradesh by 34%. The company is actively engaged in building a foothold in export markets. It has recently entered into the African market, by beginning operations in Somalia, and has received the approval for their products from the Ethiopian Food and Drug Authority (EFDA).

Checklist

Quality analysis
Revenue growth
Company valuation
Earnings expansion
Risk analysis
Debt to Equity ratio
Promoter holdings
Shares pledged
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Objectives of Avience Biomedicals Limited IPO

Capital expenditure
52.70%
The company will use ₹15.96 crore for setting up of a new manufacturing unit.
Working capital
27.20%
The company will use ₹ 8.25 crore for working capital requirements of business.
General corporate purposes
19.90%
Part of the IPO proceeds will be used for general corporate purposes and issue expenses

Compare

CompanyRevenue*3Y growthPATMarket capP/E ratioD/E ratio
This IPO₹45.24Cr88.81%₹7.24Cr₹114.09Cr10.910.97
This sector (avg.)₹810.55Cr---₹87.66Cr₹10,075.9Cr55.140.40
₹21,794Cr---₹1,472.1Cr₹1,00,081.3Cr59.860.96
₹7,028.46Cr---₹1,075.88Cr₹93,096.78Cr68.940.32
₹7,782.75Cr---₹809.39Cr₹64,284.69Cr63.430.28

*Revenue for financial year 209-10. Lower P/E and D/E ratios are generally preferred.

Avience Biomedicals IPO Contact Details

Company NameAvience Biomedicals Limited

How to apply for Avience Biomedicals IPO?

  1. Step 1

    Log in to your Upstox account to access IPO investments. Next, select the current IPO section.

  2. Step 2

    Specify IPO details. Enter the number of lots and the price you wish to apply for.

  3. Step 3

    Enter UPI ID. After entering your UPI ID, click submit. This will place your bid with the exchange.

  4. Step 4

    Mandate Notification. Your UPI app will receive a mandate notification to block funds.

  5. Step 5

    Approve Request. Your funds will be blocked once you approve the mandate request on your UPI.

Avience Biomedicals Limited IPO FAQs